Breaking News, Promotions & Moves

PCI Appoints CHRO

Angi Calkins has served in senior leadership roles at Regeneron Pharmaceuticals, a leading biotechnology company that doubled in size during her time there

PCI has appointed Angi Calkins as senior vice president and chief human resources officer. 

Angi brings significant experience to PCI in human resources leadership across multiple and diverse industries including pharmaceutical and life sciences, retail, consumer goods, global HR outsourcing and financial services. She has served in senior leadership roles at Regeneron Pharmaceuticals, a leading biotechnology company that doubled in size, was recognized each year by Forbes as one of the 100 Greatest Places to Work, and was ranked the industry’s number one Biopharma Employer by Science Magazine during three of her four years in post.

Chief executive officer Salim Haffar said, “Our company is rich in cutting-edge science and technology, rooted in a dedication to outstanding service and quality. This is achieved through a talented and dedicated workforce. I am very pleased to have Angi join at such an exciting time and am eager to see her insights and leadership help shape the future of the company.”

“I am delighted for this opportunity,” said Angi. “Across my career I have had opportunities to learn about and excel in both in-house and outsource partnership organizations, and PCI is a uniquely inspiring fit for my background and my passion for people and talent at the heart of great business. I was attracted to PCI by virtue of its outstanding reputation in the industry, its focus on continued investment and global growth, and certainly its singular commitment to delivering outstanding service and industry-leading quality for its clients, ultimately playing a critical role in the lives of our clients’ patients around the world. PCI has demonstrated through its investments and focus on developing a growing global workforce that it is committed to meeting the unique and ever-evolving needs of its clients, both in the short- and the long-term. I am excited to be part of that growth and expansion.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters